It was able to predict the efficacy of some established combination therapies for NSCLC, such as BRAF/MEK and EGFR/mTOR inhibitors, but also identified brand new recipes. For example, it suggested ...

A total of 337 treatment-naïve patients with EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC were enrolled and randomized 1:1 to receive either limertinib or gefitinib.

The drug blocks the activity of a protein known as mammalian target of rapamycin (mTOR), which promotes proliferation through the activation of proteins such as S6 kinase. Although the mTOR ...

Lazertinib is an oral, highly selective, third-generation EGFR tyrosine kinase inhibitor that can penetrate the brain, and amivantamab is a bispecific antibody targeting EGFR and mesenchymal ...